These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 25810342)

  • 1. Experimental designs for detecting synergy and antagonism between two drugs in a pre-clinical study.
    Sperrin M; Thygesen H; Su TL; Harbron C; Whitehead A
    Pharm Stat; 2015; 14(3):216-25. PubMed ID: 25810342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of the robustness of two models for assessing synergy in pre-clinical drug combination studies.
    Whitehead A; Su TL; Thygesen H; Sperrin M; Harbron C
    Pharm Stat; 2013; 12(5):300-8. PubMed ID: 23907796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A flexible unified approach to the analysis of pre-clinical combination studies.
    Harbron C
    Stat Med; 2010 Jul; 29(16):1746-56. PubMed ID: 20572122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies.
    Chou TC
    Pharmacol Rev; 2006 Sep; 58(3):621-81. PubMed ID: 16968952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statistical assessment and visualization of synergies for large-scale sparse drug combination datasets.
    Amzallag A; Ramaswamy S; Benes CH
    BMC Bioinformatics; 2019 Feb; 20(1):83. PubMed ID: 30777010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experimental design and statistical analysis for three-drug combination studies.
    Fang HB; Chen X; Pei XY; Grant S; Tan M
    Stat Methods Med Res; 2017 Jun; 26(3):1261-1280. PubMed ID: 25744107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction index and different methods for determining drug interaction in combination therapy.
    Lee JJ; Kong M; Ayers GD; Lotan R
    J Biopharm Stat; 2007; 17(3):461-80. PubMed ID: 17479394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A generalized response surface model with varying relative potency for assessing drug interaction.
    Kong M; Lee JJ
    Biometrics; 2006 Dec; 62(4):986-95. PubMed ID: 17156272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A simple test for synergy for a small number of combinations.
    Novick SJ
    Stat Med; 2013 Dec; 32(29):5145-55. PubMed ID: 23904140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantifying synergism/antagonism using nonlinear mixed-effects modeling: a simulation study.
    Boik JC; Newman RA; Boik RJ
    Stat Med; 2008 Mar; 27(7):1040-61. PubMed ID: 17768754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An R-shiny application to calculate optimal designs for single substance and interaction trials in dose response experiments.
    Holland-Letz T; Kopp-Schneider A
    Toxicol Lett; 2021 Feb; 337():18-27. PubMed ID: 33232777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experimental design and interaction analysis of combination studies of drugs with log-linear dose responses.
    Fang HB; Ross DD; Sausville E; Tan M
    Stat Med; 2008 Jul; 27(16):3071-83. PubMed ID: 18186545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fitting models for the joint action of two drugs using SAS.
    Whitehead A; Whitehead J; Todd S; Zhou Y; Smith MK
    Pharm Stat; 2008; 7(4):272-84. PubMed ID: 17979217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Robust designs in longitudinal studies accounting for parameter and model uncertainties - application to count data.
    Loingeville F; Nguyen TT; Riviere MK; Mentré F
    J Biopharm Stat; 2020; 30(1):31-45. PubMed ID: 31032703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and sample size for evaluating combinations of drugs of linear and loglinear dose-response curves.
    Fang HB; Tian GL; Li W; Tan M
    J Biopharm Stat; 2009 Jul; 19(4):625-40. PubMed ID: 20183430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of experiments for the precise estimation of dose-response parameters: the Hill equation.
    Bezeau M; Endrenyi L
    J Theor Biol; 1986 Dec; 123(4):415-30. PubMed ID: 3657186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. D-optimal experimental designs to test for departure from additivity in a fixed-ratio mixture ray.
    Coffey T; Gennings C; Simmons JE; Herr DW
    Toxicol Sci; 2005 Dec; 88(2):467-76. PubMed ID: 16162847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A mathematical approach to study combined effects of toxicants in vitro: evaluation of the Bliss independence criterion and the Loewe additivity model.
    Goldoni M; Johansson C
    Toxicol In Vitro; 2007 Aug; 21(5):759-69. PubMed ID: 17420112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A direct, general approach based on isobolograms for assessing the joint action of drugs in pre-clinical experiments.
    Machado SG; Robinson GA
    Stat Med; 1994 Nov; 13(22):2289-309. PubMed ID: 7855464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal design for estimating parameters of the 4-parameter hill model.
    Khinkis LA; Levasseur L; Faessel H; Greco WR
    Nonlinearity Biol Toxicol Med; 2003 Jul; 1(3):363-77. PubMed ID: 19330140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.